RLYB — Rallybio Corp
NASDAQ · Healthcare · Biotechnology
$16.69
-$0.10 (-0.60%)
Rallybio Corp (RLYB) is a biotechnology company listed on NASDAQ. It is led by Stephen Uden M.B, M.D., based in 234 Church Street, New Haven, CT, United States, 06510, with about 24 employees. Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Latest reported RLYB revenue for 2025-09-30 was $212.0K. Net income was $16.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. RLYB currently screens at market cap $13.8M.
Use this RLYB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RLYB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RLYB SEC filings page. Lician reads the product cache first so this HTML stays unique to Rallybio Corp even when a live quote feed is slow.
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
RLYB Key Statistics
Market Cap
$13.84M
Volume
4,465
Previous Close
$16.80
Day Range
$16.64 – $16.98
EPS
-$1.33
Revenue
$600.00K
Net Income
-$57.77M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-9629.2%
Employees
24
RLYB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $600.00K | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$57.77M | -$74.56M | -$66.65M | -$47.01M |
| EPS (Diluted) | -$1.33 | -$1.84 | -$2.09 | -$1.84 |
Total Assets
$68.11M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$13.90M
Operating Cash Flow
-$49.28M
Free Cash Flow
$0.00
Rallybio Corp Company Information
- Co-Founder, President, CEO & Director
- Stephen Uden M.B, M.D.
- Headquarters
- 234 Church Street, New Haven, CT, United States, 06510
- Website
- www.rallybio.com
- Phone
- 203 859 3820
- IPO / Founded
- 2021-07-29
- Sector
- Healthcare
- Industry
- Biotechnology